Clichy

• APIS Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension Ended recruitment
  2024-514348-95-00 5 2019-06-24 Intrahepatic non-cirrhotic portal hypertension
• Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocri … Ended recruitment
  2023-505286-84-00 4 2018-06-25 Pancreatic well differentiated neuroendocrine tumors (NET)
• A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Res … Ended recruitment
  2023-508726-10-00 5 2018-03-28 Hepatocellular Carcinoma
• This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, … Ended recruitment
  2024-512212-21-00 5 2017-11-28 Advanced hepatocellular carcinoma (HCC)
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended recruitment
  2023-510444-21-00 5 2017-11-24 Neuroendocrine tumours of gastroenteric or pancreatic origin
• A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea … Ended recruitment
  2023-506399-28-00 5 2017-11-08 Crohn's Disease
• Prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Patients with HepatoCell … Halted
  2023-508567-75-00 9 2025-01-29 Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
• A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics o … Ended
  2024-520202-19-00 4 2025-08-19 Subjects with Intestinal Failure-Associated Liver Disease (IFALD)
• Open-Label Study of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab in Subjects with Chronic HBV Infection Ended
  2023-509573-23-00 4 2024-07-16 Chronic HBV Infection
• Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7. Ended
  2022-501969-42-00 5 2024-03-28 Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criter
• A study to test whether BI 685509 helps people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liv … Ended
  2023-506083-13-00 4 2024-02-16 clinically significant portal hypertension (CSPH) in decompensated cir
• A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended
  2022-501310-57-00 4 2024-02-05 Endometriosis related pain
• FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study Ended
  2024-512913-42-00 4 2023-08-21 Severe Alcohol-Associated Hepatitis
• CA-CIBLE : Impact of increasing the ionized serum calcium target post-filter on the effectiveness of regional citrate anticoagulation during … Ended
  2024-511897-64-00 11 2023-07-01 Adult patients hospitalized in intensive care with an indication of EE
• A Study to Evaluate Investigational Therapies in Chronic Hepatitis B Virus Infection Ended
  2024-513176-17-00 4 2023-03-30 Chronic Hepatitis B Virus (HBV) Infection
• Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizu … Ended
  2024-511538-11-00 4 2023-02-07 Non resectable Hepatocellular carcinoma (HCC)
• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended
  2022-501901-10-00 6 2023-02-06 Chronic Hepatitis D Infection
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended
  2023-504239-41-00 5 2023-01-09 Hepatitis B, Chronic
• Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci … Ended
  2022-502078-17-00 4 2022-12-15 unresectable hepatocellular carcinoma
• A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended
  2023-506369-79-00 4 2022-11-30 Pancreatic ductal adenocarcinoma
• Zibotentan and Dapagliflozin combination, Evaluated in Liver cirrhosis (ZEAL study) Ended
  2023-505405-17-00 4 2022-10-07 Liver cirrhosis with features of portal hypertension.
• A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or … Ended
  2023-504257-12-00 4 2022-07-28 Portal hypertension
• Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended
  2023-503905-12-00 4 2021-08-20 Liver cancer; Colon cancer; Pancreatic cancer; Bile Duct or Gallbladde
• EASE SBS 3 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome (SBS) Ended
  2024-513373-43-00 5 2021-06-11 Short bowel syndrome

Showing 145–168 of 182 trials